<!DOCTYPE html><html lang="en" class="page"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1"><link rel="shortcut icon" href="favicon.ico" type="image/x-icon"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta name="theme-color" content="#111111"><title>Capnia guidelines</title><link rel="preload" href="fonts/WorkSansRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansMedium.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansBold.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowBold.woff2" as="font" type="font/woff2" crossorigin><link rel="stylesheet" href="css/vendor.css"><link rel="stylesheet" href="css/main.css"><script defer="defer" src="js/main.js"></script></head><body class="page__body"><a class="skiplink" href="#main-guidelines">Go to main content</a><div class="site-container"><header class="header header--products"><div class="header__container container-additional"><a class="header__logo" href="index.html"><img src="./img/logo.svg" class="header__logo-image" width="176" height="40" alt="Capnia logo"></a><nav class="header__nav" aria-label="Main navigation" data-menu><ul class="header__nav-list"><li class="header__nav-item"><a class="header__nav-link header__nav-link--home" href="index.html">Home</a></li><li class="header__nav-item"><a class="header__nav-link" href="products.html"><i>CoSense <span>®</span> </i>Product</a></li><li class="header__nav-item header__nav-item--dropdown"><button class="header__nav-link js-btn-dropdown" type="button" aria-label="Open submenu navigation">Clinical Resources</button><div class="dropdown"><div class="dropdown__wrapper"><ul class="dropdown__list"><li class="dropdown__item"><a class="dropdown__link dropdown__link--studies" href="cosense-studies.html"><span class="dropdown__link-text"><i>CoSense <span>®</span> </i></span>Studies</a></li><li class="dropdown__item"><a class="dropdown__link" href="bibliography.html">Bibliography</a></li><li class="dropdown__item"><a class="dropdown__link" href="guidelines.html">Guidelines</a></li></ul></div></div></li><li class="header__nav-item"><a class="header__nav-link" href="about.html">About Us</a></li><li class="header__nav-item"><a class="header__nav-link header__nav-link--contact" href="#">Contact Us</a></li></ul></nav><button class="header__burger" aria-label="Open menu" aria-expanded="false" data-burger><span class="header__burger-line"></span></button></div></header><main class="page__main" id="main-guidelines"><section class="clinical-resources"><div class="container"><div class="clinical-resources__wrapper"><h1 class="clinical-resources__title title-huge">Clinical Resources</h1><ul class="clinical-resources__list"><li class="clinical-resources__item"><a class="clinical-resources__link" href="cosense-studies.html"><i>CoSense</i> Studies</a></li><li class="clinical-resources__item"><a class="clinical-resources__link" href="bibliography.html">Bibliography</a></li><li class="clinical-resources__item"><a class="clinical-resources__link clinical-resources__link--active" href="guidelines.html">Guidelines</a></li></ul><div class="clinical-resources__text text-huge"><p>Review summary excerpts from the American Academy of Pediatrics (AAP) Clinical Guidelines which support the adoption of ETCOc tests for the detection and treatment of newborn babies.</p></div></div></div></section><section class="clinical-resources-info clinical-resources-info--guidelines" id="clinical-resources-info-guidelines"><div class="clinical-resources-info__container container"><div class="clinical-resources-info__wrapper"><a class="clinical-resources-info__to-top" href="#clinical-resources-info-guidelines">top</a><div class="clinical-resources-info__inner"><h2 class="clinical-resources-info__title">Clinical Guidelines</h2><ul class="clinical-resources-info__list"><li class="clinical-resources-info__item"><div class="clinical-resources-info__text text-medium"><p>American Academy of Pediatrics Clinical Guidelines 2022</p></div><ul class="clinical-resources-info__sublist"><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control accordion__control--guidelines" type="button" aria-expanded="false"><span class="accordion__title text-medium">Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. </span><span class="accordion__info text-medium">Kemper AR, Newman TB, Slaughter JL, et al. <span>Pediatrics.</span> 2022;150(3):e2022058859 </span><span class="accordion__icon"></span></button><div class="accordion__content accordion__content--guidelines text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><ul><li>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</li><li>The intervention group received risk assessment based on ETCOc: a level &lt; 1.5 ppm indicates low risk, a level ≥ 1.5 ppm indicates increased risk for hemolysis. Controls had empirical risk assessment by pediatricians per local practice with ETCOc masked.</li><li>The intervention was associated with decreased need of phototherapy in 7 DOL by 23%.</li><li>The intervention group started phototherapy earlier with higher ETCOc level but similar TCB/TSB.</li><li>No acute bilirubin encephalopathy occurred.</li><li>Risk assessment by ETCOc (vs. empirical assessment per local practice) can decrease the rate of unnecessary phototherapy by 23%.</li><li>ETCOc may be able to identify those who require phototherapy earlier.</li></ul><b>Focus of Guideline</b><p>A Single-centered <span>Pediatrics</span> unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li></ul></li><li class="clinical-resources-info__item"><div class="clinical-resources-info__text text-medium"><p>American Academy of Pediatrics Clinical Guidelines 2004</p></div><ul class="clinical-resources-info__sublist"><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion open is-open"><button class="accordion__control accordion__control--guidelines" type="button" aria-expanded="false"><span class="accordion__title text-medium">American Academy of Pediatrics Subcommittee ons Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. </span><span class="accordion__info text-medium">Maisels MJ, Baltz RD, Bhutani VK, et al. <span>Pediatrics.</span> 2004 Jul;114(1):297-316. doi: 10.1542/peds.114.1.297. </span><span class="accordion__icon"></span></button><div class="accordion__content accordion__content--guidelines text-medium" aria-hidden="true"><p>[Excerpts]</p><b>Focus of Guideline</b><p>The overall aim of this guideline is to promote an approach that will reduce the frequency of severe neonatal hyperbilirubinemia and bilirubin encephalopathy and minimize the risk of unintended harm such as increased anxiety, decreased breastfeeding, or unnecessary treatment for the general population and excessive cost and waste. Recent reports of kernicterus indicate that this condition, although rare, is still occurring.</p><p>Analysis of these reported cases of kernicterus suggests that if health care personnel follow the recommendations listed in this guideline, kernicterus would be largely preventable.</p><b>Identification of Hemolysis</b><p>Because of their poor specificity and sensitivity, the standard laboratory tests for hemolysis are frequently unhelpful. However, end-tidal carbon monoxide, corrected for ambient carbon monoxide (ETCOc), levels can confirm the presence or absence of hemolysis, and measurement of ETCOc is the only clinical test that provides a direct measurement of the rate of heme catabolism and the rate of bilirubin production. Thus, ETCOc may be helpful in determining the degree of surveillance needed and the timing of intervention. It is not yet known, however, how ETCOc measurements will affect management.</p></div></div></li></ul></li></ul></div></div></div></section></main><footer class="footer"><div class="footer__container container"><div class="footer__logo"><a class="footer__logo-link" href="index.html"><img class="footer__logo-image" src="./img/logo-footer.svg" width="174" height="39" alt="Capnia logo"></a></div><div class="footer__wrapper"><div class="footer__customer"><ul class="footer__social"><li class="footer__social-item"><a class="footer__social-link footer-link" href="privacy-statement.html">Customer Support</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--careers footer-link" href="https://www.linkedin.com/company/capnia-inc./jobs/" target="_blank">Careers</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--follow footer-link" href="https://www.linkedin.com/company/capnia-inc./about/" target="_blank">Follow Us</a></li><li class="footer__social-item"><a class="footer__social-link bilitool footer-link" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></li></ul></div><div class="footer__contact"><a class="footer__contact-link footer-link" href="#">Contact Us</a><address class="footer__contact-address footer-contact-item footer-contact-item--address">1101 Chess Drive Foster City, CA 94404</address><a class="footer__contact-tel footer-contact-item footer-contact-item--tel" href="tel:8664323788"><span class="footer__contact-text">Tel:</span> <span class="footer__contact-descr">(866) 432-3788</span> </a><a class="footer__contact-email footer-contact-item footer-contact-item--email" href="mailto:info@capnia.com"><span class="footer__contact-text">Email:</span> <span class="footer__contact-descr footer__contact-descr--email">info@capnia.com</span></a></div><a class="bilitool bilitool--mobile" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></div><div class="footer__info"><div class="footer__info-content"><span class="footer__info-item">CAPNIA, Inc. © 2024</span> <span class="footer__info-item">All Rights Reserved</span></div><div class="footer__info-content"><a class="footer__info-item" href="terms-of-use.html">Terms of Use</a> <a class="footer__info-item" href="privacy-statement.html">Privacy Statement</a></div></div></div></footer></div></body></html>